Cogent Biosciences, Inc.
About Cogent Biosciences, Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$328.9M
- Total assets
- $937.6M
- Market cap
- $5.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating income
- -$333.4M
- Income tax
- $0
- Net income
- -$328.9M
- EPS (basic)
- $-2.16
- EPS (diluted)
- $-2.16
Balance sheet
- Total assets
- $937.6M
- Current assets
- $910.4M
- Total liabilities
- $301.2M
- Current liabilities
- $64.0M
- Shareholders’ equity
- $636.4M
Cash flow
- Operating cash flow
- -$264.4M
- Investing cash flow
- -$399.5M
- Financing cash flow
- $878.2M
- Net cash flow
- $214.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.3B
- EPS (diluted)
- $-2.16
- Shares outstanding
- 170.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 29, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $328.9M.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cogent Biosciences, Inc..
Write a review
News about Cogent Biosciences, Inc.
News & sentiment via Polygon.io
